DexCom Inc. (NASDAQ:DXCM) saw strong trading volume on Friday . 1,640,305 shares were traded during trading, an increase of 53% from the previous session’s volume of 1,068,741 shares.The stock last traded at $87.98 and had previously closed at $84.63.

A number of analysts have commented on the company. BTIG Research restated a “buy” rating and issued a $92.00 price target on shares of DexCom in a research report on Tuesday. Jefferies Group restated a “buy” rating and issued a $98.00 price target (up previously from $90.00) on shares of DexCom in a research report on Friday, July 15th. Zacks Investment Research upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Tuesday. Canaccord Genuity restated a “buy” rating on shares of DexCom in a research report on Thursday, April 28th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $93.00 price target on shares of DexCom in a research report on Friday, July 15th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus price target of $94.62.

The stock’s 50 day moving average is $76.37 and its 200-day moving average is $68.73. The company’s market capitalization is $7.33 billion.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, April 27th. The medical device company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.03. The company earned $116.20 million during the quarter, compared to analysts’ expectations of $110.37 million. During the same period in the previous year, the company posted ($0.17) EPS. The firm’s quarterly revenue was up 59.6% compared to the same quarter last year. On average, equities research analysts predict that DexCom Inc. will post ($0.35) earnings per share for the current fiscal year.

In other DexCom news, CFO Jess Roper sold 3,471 shares of the business’s stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $69.00, for a total transaction of $239,499.00. Following the completion of the sale, the chief financial officer now directly owns 88,719 shares in the company, valued at approximately $6,121,611. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Richard Doubleday sold 1,666 shares of the business’s stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $69.15, for a total value of $115,203.90. Following the sale, the executive vice president now owns 94,900 shares of the company’s stock, valued at $6,562,335. The disclosure for this sale can be found here.

A number of large investors have recently bought and sold shares of DXCM. Vanguard Group Inc. raised its stake in DexCom by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 5,241,624 shares of the medical device company’s stock valued at $429,289,000 after buying an additional 184,708 shares during the period. Morgan Stanley raised its stake in DexCom by 0.6% in the fourth quarter. Morgan Stanley now owns 1,268,992 shares of the medical device company’s stock valued at $103,930,000 after buying an additional 7,662 shares during the period. Jennison Associates LLC raised its stake in DexCom by 21.6% in the fourth quarter. Jennison Associates LLC now owns 1,172,571 shares of the medical device company’s stock valued at $96,034,000 after buying an additional 208,459 shares during the period. California Public Employees Retirement System raised its stake in DexCom by 5.9% in the fourth quarter. California Public Employees Retirement System now owns 138,400 shares of the medical device company’s stock valued at $11,335,000 after buying an additional 7,700 shares during the period. Finally, Rhumbline Advisers raised its stake in DexCom by 0.5% in the fourth quarter. Rhumbline Advisers now owns 88,844 shares of the medical device company’s stock valued at $7,276,000 after buying an additional 480 shares during the period.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.